Brokerages Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Target Price at $155.60

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have received an average recommendation of “Buy” from the seventeen ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, fourteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $155.60.

PVLA has been the topic of several recent analyst reports. Raymond James Financial restated a “strong-buy” rating and set a $193.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Oppenheimer reaffirmed an “outperform” rating and set a $200.00 price objective on shares of Palvella Therapeutics in a report on Monday, December 15th. Stifel Nicolaus boosted their target price on Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. HC Wainwright set a $200.00 price target on Palvella Therapeutics and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, UBS Group reiterated a “buy” rating and issued a $143.00 price objective on shares of Palvella Therapeutics in a research report on Monday, December 15th.

Palvella Therapeutics Trading Down 2.3%

Palvella Therapeutics stock opened at $103.37 on Thursday. The stock has a 50 day moving average of $88.84 and a two-hundred day moving average of $60.19. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $114.69. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -39.30 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). Equities analysts predict that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total value of $415,013.94. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Archer Investment Corp acquired a new stake in Palvella Therapeutics during the 3rd quarter valued at $28,000. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Palvella Therapeutics during the second quarter valued at $37,000. AlphaQuest LLC acquired a new stake in shares of Palvella Therapeutics during the third quarter valued at $164,000. Finally, JPMorgan Chase & Co. increased its position in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.